Since their introduction in 1987, statins have accumulated an extensive amount of data in randomized clinical trials and clinical use. The studies included in the Cholesterol Treatment Trialists’ (CTT) Collaboration meta-analyses have shown that statins are clearly effective in reducing the risk of major atherosclerotic cardiovascular events1 and that the cardiovascular benefits outweigh the risks of treatment. Several statins are available in generic form and are therefore cost-effective. However, for a significant number of patients statin therapy is discontinued because of intolerance, ie, adverse events perceived to be caused by the statin, most commonly muscle pain, aching, or weakness, usually without significant elevations in levels of creatine kinase.2
Newman CB, Tobert JA. Statin Intolerance: Reconciling Clinical Trials and Clinical Experience. JAMA. 2015;313(10):1011–1012. doi:10.1001/jama.2015.1335
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.